151 related articles for article (PubMed ID: 18176193)
1. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Alexander S; Hopewell S; Hunter S; Chouksey A
J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
[TBL] [Abstract][Full Text] [Related]
2. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
[No Abstract] [Full Text] [Related]
3. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
Bon A; Morfini M; Dini A; Mori F; Barni S; Gianluca S; de Martino M; Novembre E
Ital J Pediatr; 2015 Feb; 41():12. PubMed ID: 25887512
[TBL] [Abstract][Full Text] [Related]
4. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
6. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Gamerman S; Singh AM; Makhija M; Sharathkumar A
Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
[No Abstract] [Full Text] [Related]
7. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Chitlur M; Warrier I; Rajpurkar M; Lusher JM
Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
[TBL] [Abstract][Full Text] [Related]
8. Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Holstein K; Schneppenheim R; Schrum J; Bokemeyer C; Langer F
Hamostaseologie; 2014; 34 Suppl 1():S5-8. PubMed ID: 25382771
[TBL] [Abstract][Full Text] [Related]
9. Development of anaphylactic shock in haemophilia B patients with inhibitors.
Warrier I; Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
[TBL] [Abstract][Full Text] [Related]
10. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
Curry NS; Misbah SA; Giangrande PL; Keeling DM
Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors in haemophilia B: the Italian experience.
Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
[TBL] [Abstract][Full Text] [Related]
12. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
13. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
Barnes C; Rudzki Z; Ekert H
Haemophilia; 2000 Nov; 6(6):693-5. PubMed ID: 11122398
[TBL] [Abstract][Full Text] [Related]
14. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
16. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
Greenmyer JR; Grindeland CJ; Kobrinsky NL
Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
[No Abstract] [Full Text] [Related]
17. [Factor IX inhibitor in hemophilia B presented with anaphylactoid symptoms: report of 3 cases].
Taketani T; Hanada R; Kawaguchi H; Ida K; Yamamoto K
Rinsho Ketsueki; 1999 Oct; 40(10):1124-6. PubMed ID: 10565232
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor development in haemophilia B: an orphan disease in need of attention.
DiMichele D
Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
[TBL] [Abstract][Full Text] [Related]
19. Current management of hemophilia B: recommendations, complications and emerging issues.
Franchini M
Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for adolescents with haemophilia and high titre inhibitors.
Fox RA; Neufeld EJ; Bennett CM
Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
